The general mood among these heavyweight investors is divided, with 63% leaning bullish and 36% bearish. Among these notable ...

Recently reported positive preliminary data from Phase 1 dose escalation trial of micvotabart pelidotin ("MICVO," formerly PYX-201), including a confirmed 50% objective response rate by RECIST 1.1 ...

We recently published a list of 10 Most Undervalued S&P 500 Stocks to Buy Now. In this article, we are going to take a look at where Merck & Co Inc. (NYSE:MRK) stands against other undervalued S&P 500 ...

Merck & Co Inc. has become a top contender for the most profitable value stock, but it faces some challenges. Merck boasts a forward P/E ratio of 10.36 and TTM net income of $17.117 billion. Despite ...

As Trump begins to ramp up a crackdown at the border and migration levels to the U.S. dip, smugglers say new technologies ...

Merck KGaA's stock remains a 'hold' due to its high valuation, trading at an earnings multiple of around 20 and a 4.5% free ...

Merck & Co. ranks among the top dividend contenders, having increased payouts for 14 consecutive years. Dividend stocks ...

Top 15. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other top dividend ...

DURHAM, N.C.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the opening of a new, $1 billion, 225,000-square-foot facility dedicated to ...

Preparations for submission of a Biologics License Application (BLA) for Cylembio® (imsapepimut and etimupepimut, adjuvanted) to FDA by year end 2025 remain on track. The trial completed enrollment in ...

Merck, also known as MSD outside the U.S. and Canada, plans to significantly expand its workforce in India, aiming for around 2,700 employees by the year's end. The company focuses on therapy areas ...

I want to note that Keytruda's exclusivity ends in 2028 only in the USA, while Europe will not see its biosimilars until 2031 and Japan until 2032/2033. So, from Merck's pipeline of experimental ...